Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases

British Journal of Dermatology

Volumn 175, Issue 6, 2016, Pages 1382-1386

  Borradori, L ^a,b   Sutton, B ^a   Shayesteh, P ^a   Daniels, G A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; VISMODEGIB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADJUVANT RADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARM AMPUTATION; AXILLA; BASAL CELL CARCINOMA; BONE METASTASIS; BRAIN DAMAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CERVICAL LYMPH NODE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FACIAL BONE; FATIGUE; FOREHEAD; FRONTAL BONE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALE; MIDDLE AGED; MULTIPLE PULMONARY NODULES; NEUROIMAGING; NEUROPATHY; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; POSTOPERATIVE ILEUS; PRIORITY JOURNAL; SCALP; SHOULDER; SKIN CARCINOMA; SKULL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; X-RAY COMPUTED TOMOGRAPHY; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CASE REPORT; FACIAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; PROCEDURES; SALVAGE THERAPY; SKIN NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, BASOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; FACIAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SALVAGE THERAPY; SCALP; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84986899834     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14642     Document Type: Letter

References (15)

1. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013; 68:957–66.
2. Jarkowski A 3rd, Hare R, Loud P et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature. Am J Clin Oncol 2014; DOI: 10.1097/COC0000000000000088.
3. Stratigos A, Garbe C, Lebbe C et al. European Dermatology Forum (EDF); European Association of Dermato-Oncology (EADO); European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51:1989–2007.
4. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348:56–61.
5. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015; 37:764–82.
6. Darb-Esfahani S, Kunze CA, Kulbe H et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2016; 7:1486–99.
7. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124–8.
8. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509–20.
9. Al-Rohil RN, Tarasen AJ, Carlson JA et al. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer 2016; 122:249–57.
10. Clark RA, Huang SJ, Murphy GF et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008; 205:2221–34.
11. Chang AL, Kim J, Luciano R et al. A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatol 2016; 152:106–8.
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228–47.
13. Cao Y, Zhang L, Kamimura Y et al. B7-H1 overexpression regulates epithelial–mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res 2011; 71:1235–43.
14. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 2015; 51:221–8.
15. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375–91.